AMCO was instructed by a diagnostics company developing biomarker-based blood tests for early disease detection. The company required an IP valuation to pursue a partnership with a global diagnostics group looking to expand its early detection capabilities.
We identified and evaluated patents, research data, and proprietary biomarker panels, considering the demand for non-invasive diagnostics. Our valuation reflected the company’s potential impact in early disease screening and market growth in preventive healthcare.
The valuation enabled the company to form a strategic partnership, enhancing its distribution capabilities and expanding its diagnostic offerings to a larger network of healthcare providers.
London Office
First Floor, 85 Great Portland Street, London, W1W 7LT
New York Office
3rd Floor, 1178 Broadway, New York, NY 10001, United States
Copyright © AMCO AGENCY LTD | All Rights Reserved | Website by Dentify Digital